GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

“If you have thinner bone density, it means you don’t have as much good structure there and you could be at increased ... This may be particularly relevant now in the world of GLP-1 medications, such ...

General Motors is laying off about 1,000 workers worldwide, shedding costs as it tries to compete in a crowded global ...

A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...

The following is a summary of “Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized ...

There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

Over the past three decades, there has been a startling increase in the prevalence of obesity across the U.S., at least ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...